These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7444139)

  • 1. Clinical study of detorubicin. EORTC Clinical Screening Group.
    Recent Results Cancer Res; 1980; 74():184-91. PubMed ID: 7444139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary results of a phase II trial on solid tumors of detorubicin, a new anthracyclin.
    Cancer Clin Trials; 1980; 3(2):115-20. PubMed ID: 7428135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detorubicin--an active anthracycline in untreated metastatic melanoma.
    Chawla SP; Legha SS; Benjamin RS
    J Clin Oncol; 1985 Nov; 3(11):1529-34. PubMed ID: 4056844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.
    Lopez M; Di Lauro L; Papaldo P; Ganzina F; Di Pietro N; Lazzaro B
    Cancer Treat Rep; 1986 Jul; 70(7):911-2. PubMed ID: 3459575
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of idarubicin in advanced endometrial carcinoma.
    Hakes TB; Raymond V
    Cancer Treat Rep; 1987 May; 71(5):535-6. PubMed ID: 3471330
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
    Wander HE; Meyer D; Schuff-Werner P; Nagel GA
    Onkologie; 1986 Aug; 9(4):236-8. PubMed ID: 3531951
    [No Abstract]   [Full Text] [Related]  

  • 7. Experimental and clinical activity of a new anthracycline derivative: detorubicin (14-diethoxyacetoxydaunorubicin).
    Maral R; Heusse D; Lavelle F; Cueille G; Marlard M; Jacquillat C; Maral J; Auclerc MF; Weil M; Auclerc G; Bernard J
    Recent Results Cancer Res; 1980; 74():172-83. PubMed ID: 7444138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
    Smith DB; Howell A
    Eur J Cancer Clin Oncol; 1987 Apr; 23(4):391-4. PubMed ID: 3475204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of idarubicin in patients with advanced lymphoma.
    Gillies H; Liang R; Rogers H; Harper P; Parapia L; Cox G; Johnson S
    Cancer Chemother Pharmacol; 1988; 21(3):261-4. PubMed ID: 3162850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of idarubicin in advanced cervical carcinoma.
    Hakes TB; Dougherty JB; Raymond V
    Am J Clin Oncol; 1986 Jun; 9(3):262-3. PubMed ID: 3460321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
    Bastholt L; Dalmark M
    Cancer Treat Rep; 1987 May; 71(5):451-4. PubMed ID: 3471329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
    Deprez-de Campeneere D; Baurain R; Trouet A
    Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.
    Hochster HS; Green MD; Blum RH; Wernz JC; Speyer JL; Muggia FM
    Invest New Drugs; 1986; 4(3):275-8. PubMed ID: 3469171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of detorubicin in malignant mesothelioma.
    Colbert N; Vannetzel JM; Izrael V; Schlienger M; Milleron B; Blanchon F; Herman D; Akoun G; Roland J; Chatelet F
    Cancer; 1985 Nov; 56(9):2170-4. PubMed ID: 3902205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.
    Madon E; Grazia G; De Bernardi B; Comelli A; Carli M; Sainati L; Paolucci G; Canino R; Colella R; Bagnulo S
    Cancer Treat Rep; 1987 Sep; 71(9):855-6. PubMed ID: 3476202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phase II study of 4-demethoxydaunorubicin in metastatic breast neoplasms].
    Lionetto R; Ardizzoni A; Repetto L; Pronzato P; Sertoli MR; Rosso R
    G Ital Chemioter; 1985; 32(1):59-60. PubMed ID: 3868637
    [No Abstract]   [Full Text] [Related]  

  • 17. [A phase I trial of idarubicin by oral administration].
    Ogawa M; Kimura K; Taguchi T; Wakui A; Hattori M; Shimoyama T; Fujita H
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1896-900. PubMed ID: 3473981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New anthracyclines in the treatment of solid tumors in the advanced stage].
    Pannuti F; Martoni A; Lelli G; Camaggi CM; Strocchi E; Fruet F
    G Ital Chemioter; 1985; 32(1):49-56. PubMed ID: 3868636
    [No Abstract]   [Full Text] [Related]  

  • 19. [Results of a phase I-II clinical trial of Emoxyl, a novel antineoplastic anthracycline].
    Korman DB; Mikaélian SG; Boronovskaia LE; Maslova IA
    Vopr Onkol; 2004; 50(2):202-7. PubMed ID: 15176224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study.
    Bruzzone M; Chiara S; Falcone A; Graziani G; Conte PF; Rosso R
    Chemioterapia; 1987 Apr; 6(2):137-9. PubMed ID: 3474080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.